Impact of a Prior Non-Pancreatic Malignancy on Survival Outcomes of Patients with Stage IV Pancreatic Neuroendocrine Tumor: a Population Based and Propensity Score Matching Study

Gang Li,Dianrong Xiu

DOI: https://doi.org/10.1016/j.hpb.2019.10.2173

IF: 3.842

2019-01-01

HPB

Abstract:Introduction: Pancreatic neuroendocrine tumor (PanNET) have great variance in biological behavior. During the course of this disease, Up to 60–80% of patients develop distant metastasis. Patients suffering with malignancy have a higher risk of developing a secondary cancer in the subsequent survival period. Whether the history of a prior non-pancreatic cancer has an impact on the survival of patients with stage IV PanNET is rarely elucidated. Method: Surveillance, Epidemiology, and End Results database were reviewed and the patients with stage IV PanNET diagnosed between 2004 and 2015 were selected. Patients were divided into two groups according to the presence or absence of a prior non-pancreatic malignancy. Before and after propensity score matching (PSM), clinico-pathological characteristics were compared. The OS and CSS were also studied. Result: After excluding unqualified patients, a total of 1582 patients with stage IV PanNET diagnosed 2004-2015 were identified, of whom 116 (7.3%) had a prior malignancy. Prostate (33.62%), breast (17.24%), and gastrointestinal (12.07%) malignancies were the most common prior cancer type. Most of the prior malignancies (84.48%) were localized and regional. Patients with interval months of ≤36 months, 36-60 months, 60-120 months, and >120months account for 25.86%, 14.66%, 31.03%, and 28.45% of all cases with prior cancer, respectively. Before PSM, patients with prior cancer was associated with increasing age (p<0.001), later year of diagnosis (p=0.001), and less proportion of chemotherapy (p=0.001). Before and after PSM, no significant difference was found regarding both OS and CSS. The different clinical stages and locations of prior cancer had no effect on CSS. Conclusion: Stage IV PanNET patients with a history of prior cancer had comparable survival outcome with patients without prior cancer. Stage IV PanNET patients with a prior cancer could be candidates for clinical trials if otherwise appropriate, and aggressive and potentially curative therapies should be offered for these patients.